Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,754Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-69.1EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)21.3Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %2.1PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M12,000,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IYH

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

IYH is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

IYH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.481442.19view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94763.05view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1785900view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.3610650view
Bebek, IvanDirector 2017-01-16Buy8,990$3.384225.44view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4135558.54view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91423.83view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.272231.74view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38142.13view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1597366.67view

Quarterly/Annual Reports about IYH:

    News about IYH:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    A Look Into The Economic And Human Cost Of A Partial Obamacare Repeal Jan 12 2017
    Gilead Sciences’ Liver Disease Drugs Portfolio Jan 02 2017
    What Factors Are Contributing to Gilead Sciences’ Growth? Dec 30 2016
    The Competitive Landscape for Enbrel Dec 29 2016
    What’s Behind Amgen’s Discounted Valuation? Dec 28 2016
    2 Beaten-Down Funds To Buy For 9.4% Dividends - And 3 To Avoid Dec 24 2016
    Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug Dec 21 2016
    Pfizer Has Strong Track Record since 2010 Dec 15 2016
    How Much Could Pfizer Grow beyond 2016? Dec 14 2016
    Lyrica to Lose Patent Protection in the US in 2018 Dec 14 2016
    Listing the Reasons behind Pfizer’s Discounted Price-to-Earnings Dec 09 2016
    Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares Dec 07 2016
    The Fuel for Today’s Reflationary Fire: What You Need to Know Dec 02 2016
    Which US Sectors Look Appealing in the Reflationary Environment? Dec 02 2016
    These Pfizer Products Saw Falling Revenues in 3Q16 Nov 30 2016
    Pfizer’s Innovative and Essential Health Businesses Nov 30 2016
    Is Gilead Sciences Stock Oversold? Nov 28 2016
    These Will Be the Challenges to BMY’s Opdivo in the Lung Cancer Space Nov 22 2016
    Inside Bristol-Myers Squibb’s Upward Revision of Guidance Nov 22 2016
    Inside Eli Lilly’s Revenue Trends Nov 22 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)